))
Sex and gender in medical research: how can a focus on the individual improve health outcomes for marginalised groups?
Manage episode 380850641 series 2994360
Content provided by Adam.Roberts@ttp.com and TTP plc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Adam.Roberts@ttp.com and TTP plc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Throughout almost all of medical history, it was assumed that the average white male response to drug trials could be extrapolated to all potential recipients. But when we look at the poorer health outcomes for women and minorities, could the underlying assumptions in medical research be a contributing factor? If so, what is being done to solve them?
To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.
This Week's Guests
Diana Torgersen
Diana Torgersen is the Executive Director for External Innovation & Emerging Science at Organon. Organon is a global healthcare company with a portfolio of therapies and product's in women's health, biosimilars, and established medicines across a wide array of conditions and diseases.
Shirin Heidari
Shirin Heidari is the Founding President of GENDRO, a not-for-profit organisation with a mission to advance equity through sex and gender senstive-research across discplines by creating public awareness about the implications of lack of sex and gender considerations in research and innovation.
Deana Mohr
Deana Mohr is CEO of MUVON Therapeutics. MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles.
23 episodes
Share
